Collegium Pharmaceutical, Inc. (COLL)
COLLNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$24.65
-0.0600 (-0.24%) today
At the close, Nov 9, 4:00 PM ET. Pre-market $24.82 +0.45%
- Market cap
- $771.29m
- P/E
- 3.7
- EPS, last 4 quarters
- $6.63
- Dividend yield
- –
- Day range
- –
- 52-week range
- $21.43 to $50.79
- Average volume
- 792.5k
- Previous close
- $24.71
Analysts
6 coveringBuy5 buy, 1 hold, 0 sell
Targets a year out average $46.67, +89.3% from here
Earnings
next estimate $1.69Next report
Dec 2025
-8.0%
Mar 2026
+21.9%
Jun 2026
+6.1%
Sep 2026
+11.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $205.45m | $193.52m | $199.88m | $216.34m |
| Gross profit | $128.38m | $117.25m | $110.29m | $125.42m |
| Operating income | $60.76m | $30.90m | $3.70m | $28.72m |
| Net income | $16.96m | $14.50m | -$15.05m | $21.76m |
Last four quarters: revenue $815.19m, margin 4.7%, free cash flow $336.29m
News
8 latest- IRWD Q3 Earnings Beat, Revenues Miss, 2026 View Raised, Stock UpZacks · 4 days ago
- Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 GuidanceFintel · 5 days ago
- Collegium (COLL) Q3 2026 Earnings Call TranscriptThe Motley Fool · 5 days ago
- Collegium Pharmaceutical Q3 Earnings Call HighlightsMarketBeat · 5 days ago
- Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue EstimatesZacks · 5 days ago
- Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key MetricsZacks · 5 days ago
- COLL or SDZNY: Which Is the Better Value Stock Right Now?Zacks · 6 days ago
- Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to DeclineZacks · Oct 29, 2026
The company
Collegium Pharmaceutical is a dynamic, biopharmaceutical company delivering medicines with formulation and delivery innovation for people living with complex central nervous system and pain conditions. Collegium has spent more than a decade proving that responsible stewardship and bold, science-backed approaches can redefine what treatment looks like in categories too often shaped by complexity and misconceptions. With a portfolio of differentiated ADHD medications, anchored by JORNAY PM (methylphenidate HCl) CII and AZSTARYS (serdexmethylphenidate and dexmethylphenidate) CII, and an established leadership position in responsible pain management, Collegium leads with the scientific rigor and commercial expertise to deliver treatment options around how people live their lives.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- collegiumpharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.